Sciele Pharma, Inc. (NASDAQ: SCRX) announced the completion of a pivotal Phase III program to support an NDA filing for glycopyrrolate liquid. Glycopyrrolate is being studied for use by pediatric pati… more →
Health News Bloghealtherm2 wrote 3 weeks ago: Sciele Pharma, Inc. (NASDAQ: SCRX) announced the completion of a pivotal Phase III program to suppor … more →
healtherm2 wrote 3 weeks ago: Sciele Pharma, Inc. (NASDAQ: SCRX) announced the completion of a pivotal Phase III program to suppor … more →
crimsoncanary wrote 3 months ago: Sciele Pharma have completed a phase III trial for Glycopyrrolate Liquid for the treatment of chroni … more →